



Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2017 Results

October 24, 2017

Conference Call and Webcast Scheduled for November 1, 2017

SAN DIEGO, Oct. 24, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report third quarter 2017 results after the Nasdaq market close on November 1, 2017. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update that day at 5:00pm Eastern Time (2:00pm Pacific Time).

Participants can access the live conference call by dialing 866-831-8713 (US) or 203-518-9713 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at <http://www.neurocrine.com>.

If you are unable to attend the webcast and would like further information on this announcement, please contact the Investor Relations Department at IR@neurocrine.com. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-839-4013 (US) or 402-220-2982 (International) using the conference ID: NBIX. The call will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company markets INGREZZA® (valbenazine) capsules in the United States for the treatment of adults with tardive dyskinesia. INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first FDA approved product indicated for the treatment of adults with tardive dyskinesia. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

View original content: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-third-quarter-2017-results-300542286.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Investor Relations, IR@neurocrine.com